Related Experiment Video
Updated: May 5, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
The rationale for targeted therapies in medulloblastoma
Tobey J MacDonald1, Dolly Aguilera, Robert C Castellino
1Corresponding author: Robert C. Castellino, MD, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Health Sciences Research Building, 1760 Haygood Drive NE, Room E394, Atlanta, GA 30322. rccaste@emory.edu.
Abstract:
Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Patients with MB who are classified as having high-risk disease or those with recurrent disease respond poorly to current therapies and have an increased risk of MB-related mortality. Preclinical studies and molecular profiling of MB tumors have revealed upregulation or activation of several key signaling pathways such as the sonic hedgehog and WNT pathways. Although the exact mechanisms underlying MB tumorigenesis remain poorly understood, inhibiting these key pathways with molecularly targeted therapies represents an important approach to improving MB outcomes. Several molecularly targeted therapies are already under clinical investigation in MB patients. We discuss current preclinical and clinical data, as well as data from clinical trials of targeted therapies that are either ongoing or in development for MB.
Insights
Targeted therapies show promise for treating high-risk and recurrent medulloblastoma (MB), a common childhood brain tumor. Research is exploring inhibitors of key signaling pathways to improve patient outcomes.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Molecular biology
Background:
- Medulloblastoma (MB) is the most common malignant pediatric brain tumor.
- High-risk or recurrent MB cases have poor prognoses with current treatments.
- Key signaling pathways like sonic hedgehog and WNT are implicated in MB development.
Purpose of the Study:
- To review current preclinical and clinical data on targeted therapies for medulloblastoma.
- To discuss ongoing and developing clinical trials for MB targeted treatments.
Main Methods:
- Review of preclinical studies and molecular profiling of medulloblastoma tumors.
- Analysis of clinical trial data for targeted therapies in MB patients.
Main Results:
- Upregulation of sonic hedgehog and WNT pathways is observed in MB.
- Targeted inhibition of these pathways is a promising therapeutic strategy.
- Several targeted therapies are currently under clinical investigation for MB.
Conclusions:
- Targeted therapies offer a potential approach to improve outcomes for children with high-risk or recurrent medulloblastoma.
- Further clinical investigation is crucial to establish the efficacy of these novel treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle